MassBio panel tackles why rare disease treatments cost so much

Home › MassBio panel tackles why rare disease treatments cost so much

David Meeker, right, CEO of Genzyme Corp., speaks at a panel on pricing of rare disease therapies at the MassBio annual meeting.

06.10	Hurricane Milton Public Advisory Number 5A
06.10	Summary for Hurricane Milton (AT4/AL142024)
06.10	Atlantic Tropical Weather Outlook
06.10	Eastern North Pacific Tropical Weather Outlook
06.10	Glatfelter Develops Biobased Espresso Lid Material
06.10	Tropical Storm Milton Potential Storm Surge Flooding Map
06.10	Tropical Storm Milton Probabilistic Storm Surge Graphics
06.10	Firms urge mayor to rethink congestion charge plan
More »

je.st